Logo

BioNanomatrix Receives $240K NCI Grant, Fresh VC Cash

May 17, 2006

NEW YORK, May 17 (GenomeWeb) - BioNanomatrix today said that it has been awarded a grant from the National Cancer Institute as well as new seed financing from two venture investors, 21 Ventures and Ben Franklin Technology Partners of Southeastern Pennsylvania.

 

BioNanomatrix CEO Michael Boyce-Jacino told GenomeWeb News that the NCI grant is a two-year, $240,000 SBIR Phase I grant for development of a cancer diagnostic prototype.  

 

Boyce-Jacino added that 21 Ventures will provide bridge financing to help support the company until its expected Series A financing closes later this year, while Ben Franklin Technology Partners of Southeastern Pennsylvania has made a seed investment in the company.

 

He declined to provide more information on how much 21 Ventures and Ben Franklin Partners have invested in BioNanomatrix.

Breaking News
The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.